Whither the Attenuated Psychosis Syndrome?
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
After 4 years of debate, a decision has been made. The attenuated psychosis syndrome (APS) will not be a coded diagnosis in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Formerly known as the psychosis risk syndrome, the proposed diagnosis was based on criteria developed in the mid-1990s that were informed by a comprehensive review of retrospective studies on the prodromal phase of nonaffective psychosis.1 These criteria aimed to identify prospectively people in the prodrome of schizophrenia and other psychotic disorders and have been variously titled “ultra high risk (UHR),” “clinical high risk (CHR),” “at risk mental state (ARMS),” and the “prodromal stage,” and included a group with attenuated (subthreshold) positive psychotic symptoms.2 The criteria are associated with rates of onset of psychotic disorder substantially higher than in the general population3 and other clinical populations.4 A recent meta-analysis reported the rate of onset of a psychotic disorder to be 36% after 3 years.5 About 73% of those developing a psychotic disorder fulfill criteria for schizophrenia spectrum psychoses.6 It should be noted that these data are from treated samples consisting of patients referred to specialist clinical services. Despite the consistent finding that there is a high risk of developing a psychotic disorder associated with the APS group,5 there has been considerable controversy around the idea of formally codifying it into a DSM5 diagnosis. Indeed, we, the authors of this communication, all active researchers in the area, have had differences in opinion about the merits of including APS as a new diagnosis in the DSM.7–12 One issue debated was the tension between the possibility of early intervention to prevent progression of disorder vs potential unnecessary diagnosis and treatment of what might be a self-limiting phase. The possibility of stigma and discrimination was also raised.10,11 Some speculated that a formal diagnosis would be assumed to equate to an indication for antipsychotic medication and so increase the likelihood of antipsychotic prescription.11 Others argued that the absence of an APS diagnosis has led to some clinicians using the term psychosis NOS (not otherwise specified), which may lead to antipsychotic prescription. The APS as an alternative to this diagnosis could then actually reduce antipsychotic prescribing.9,12 Importantly, an APS diagnosis will enable evidence-based treatments to be developed, including psychological therapies, and could therefore decrease antipsychotic use.12 Ultimately, the decision to exclude APS as a coded diagnosis was made not in response to any of the above issues or in the light of data addressing the principal disputes but because data on the diagnostic reliability of APS in clinical practice were limited and inconclusive. Following this decision, some critics have been quick to denounce the whole APS/ultra high-risk/clinical high-risk/prodromal concept.13–15 We, therefore, feel it is timely, as a group involved in high-risk (prodromal) research, to document some points of consensus between us and highlight areas for future research. Attempts to recognize the prodrome of schizophrenia prospectively have been active for nearly 20 years.2 Many samples of persons meeting high-risk criteria have been seen and evaluated. A strong consensus exists that individuals meeting APS criteria (which includes a criterion for help-seeking) are symptomatic and in need of clinical care.16–18 People meeting the criteria do in fact fulfill the broad definition of mental disorder: “a clinically significant behavioral and psychological syndrome or pattern … that is associated with present distress … or disability … or with a significantly increased risk of suffering death, pain, disability, or an important loss of freedom,”19 (p. xxi). Thus, treatment is clearly justified, regardless of the justification of reduction of risk or prevention. We agree that this treatment should include monitoring of mental state, supportive therapy, and attention to current practical needs. Cognitive therapy and omega-3 fatty acids may also be helpful. On current evidence, antipsychotic medication is no more effective than other more benign treatments and so is typically not recommended.20 A second point of consensus is that people meeting APS criteria have a greatly increased risk of developing a psychotic disorder within a brief time frame.3,5,21,22 Despite evidence that the transition rate (conversion from high-risk state to first-episode psychosis) may be declining in the short term23 and the finding of low rate of psychosis in recent intervention trials,24,25 its magnitude is similar to other risk syndromes,26,27 and still in the order of hundreds fold above the risk of the general population. Given this, we agree that regular assessment of mental state to detect first episode of psychosis is indicated. The monitoring of mental state and early detection of psychosis al
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Green, J. G., McLaughlin, K. A., Berglund, P. A., Gruber, M. J., Sampson, N. A., Zaslavsky, A. M., & Kessler, R. C. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.186 · Cited by 2,323
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Self-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Self-citationCannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.3 · Cited by 1,269
Self-citationThe Prodromal Phase of First-episode Psychosis: Past and Current Conceptualizations
Yung, A. R., & McGorry, P. D. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.353 · Cited by 1,168
Self-citationPsychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
Self-citationAmminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Self-citationCognitive Functioning in Prodromal Psychosis: A Meta-analysis
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., Stieglitz, R.-D., Vita, A., McGuire, P., & Borgwardt, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1592 · Cited by 691
Self-citationRuhrmann, S., Schultze-Lutter, F., Salokangas, R. K. R., Heinimaa, M., Linszen, D., Dingemans, P., Birchwood, M., Patterson, P., Juckel, G., Heinz, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.206 · Cited by 632
Cited by
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Self-citationDeveloping Psychosis and Its Risk States Through the Lens of Schizotypy
Debbane, M., Eliez, S., Badoud, D., Conus, P., Fluckiger, R., & Schultze-Lutter, F. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu176 · Cited by 245
“40 Thus, while current CHR criteria already provide good starting-points to detect emerging psychotic disorders, the predictive and discriminative power to parse noncon-verters from converters should be further improved to identify a target group for specific preventive interventions.”
BackgroundSelf-citationFusar‐Poli, P., Cappucciati, M., Rutigliano, G., Schultze‐Lutter, F., Bonoldi, I., Borgwardt, S., Riecher‐Rössler, A., Addington, J., Perkins, D., Woods, S. W., et al. (2015) · World Psychiatry · doi:10.1002/wps.20250 · Cited by 234
Self-citationValmaggia, L. R., Stahl, D., Yung, A. R., Nelson, B., Fusar-Poli, P., McGorry, P. D., & McGuire, P. K. (2013) · Psychological Medicine · doi:10.1017/s0033291713000251 · Cited by 121
Self-citationFusar-Poli, P., Frascarelli, M., Valmaggia, L., Byrne, M., Stahl, D., Rocchetti, M., Codjoe, L., Weinberg, L., Tognin, S., Xenaki, L., et al. (2015) · Psychological Medicine · doi:10.1017/s003329171400244x · Cited by 73
“…a clinical high-risk state for psychosis (HR), also known as the ‘at-risk-mental-state’, ‘prodromal’ and ‘ultra-high-risk’ (Schultze-Lutter et al. 2011; Yung et al. 2012), has allowed the identification of subjects with a 30% risk of developing schizophrenia spectrum psychoses (Fusar-Poli et al.…”
BackgroundSelf-citation
Metadata
- Authors
- Yung, A. R., Woods, S. W., Ruhrmann, S., Addington, J., Schultze-Lutter, F., Cornblatt, B. A., Amminger, G. P., Bechdolf, A., Birchwood, M., Borgwardt, S., Cannon, T. D., de Haan, L., French, P., Fusar-Poli, P., Keshavan, M., Klosterkotter, J., Kwon, J. S., McGorry, P. D., McGuire, P., Mizuno, M., Morrison, A. P., Riecher-Rossler, A., Salokangas, R. K. R., Seidman, L. J., Suzuki, M., Valmaggia, L., van der Gaag, M., Wood, S. J., & McGlashan, T. H.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-01
- Volume
- 38
- Issue
- 6
- Pages
- 1130-1134
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2106488695
- Cited by
- 97
- References
- 16
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Whither the Attenuated Psychosis Syndrome? https://app.cochat.ai/papers/10.1093/schbul/sbs108
- The paper
- Yung, A. R., Woods, S. W., Ruhrmann, S., Addington, J., Schultze-Lutter, F., Cornblatt, B. A., Amminger, G. P., Bechdolf, A., Birchwood, M., Borgwardt, S., Cannon, T. D., de Haan, L., French, P., Fusar-Poli, P., Keshavan, M., Klosterkotter, J., Kwon, J. S., McGorry, P. D., McGuire, P., . . . McGlashan, T. H. (2012). Whither the Attenuated Psychosis Syndrome? Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbs108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.